HCM vs AMLX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
HCM · Hutchmed (China)$15.16 ▲ 6.76%
AMLX · Amylyx Pharmaceuticals$29.50 ▲ 6.81%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- HCM +0.5%
- AMLX +142.2%
Head to head
| Metric | HCM | AMLX |
|---|---|---|
| Price | $15.16 | $29.50 |
| Change today | ▲ 6.76% | ▲ 6.81% |
| Market cap | $2.64B | $3.79B |
| Return, 3 months | +20.8% | +30.1% |
| Return, year to date | +13.7% | +144.2% |
| Return, 1 year | +1.4% | +139.6% |
| P/E (TTM) | 189.5 | – |
| P/B | 2.1 | 5.0 |
| P/E percentile vs own 5y | 97th | 3rd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +37.3% | – |
| Net profit growth (YoY) | -81.3% | -4.8% |
| Gross margin | 41.6% | – |
| Operating margin | -5.7% | – |
| Net margin | 3.3% | – |
| Return on equity | 1.4% | -74.7% |
| Analyst target vs. price | +20.4% | +56.4% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 63 | 54 |
| 30-day volatility | 44.6% | 49.1% |
| Max drawdown, 1 year | -37.8% | -33.6% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AMLX is the largest of the group by market value.
- AMLX has returned the most over the past year.
- HCM has been the calmest stock over the last 30 days.